Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-21093
Springer, B; Lucke, K; Calligaris-Maibach, R; Ritter, C; Böttger, E C (2009). Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. Journal of Clinical Microbiology, 47(6):1773-1780.
Since numbers of drug-resistant Mycobacterium tuberculosis strains are on the rise, the simple classification into "susceptible" and "resistant" strains based on susceptibility testing at "critical concentrations" has to be reconsidered. While future studies have to address the correlation of phenotypic resistance levels and treatment outcomes, a prerequisite for corresponding investigations is the ability to exactly determine levels of quantitative drug resistance in clinical M. tuberculosis isolates. Here we have established the conditions for quantitative drug susceptibility testing for first- and second-line agents using MGIT 960 instrumentation and EpiCenter software equipped with the TB eXiST module. In-depth comparative analysis of a range of well-characterized susceptible and resistant clinical isolates has allowed us to propose conditions for testing and to develop criteria for interpretation.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Institute of Medical Microbiology|
|DDC:||570 Life sciences; biology|
610 Medicine & health
|Deposited On:||05 Oct 2009 14:45|
|Last Modified:||27 Nov 2013 17:40|
|Publisher:||American Society for Microbiology|
|Additional Information:||Copyright © American Society for Microbiology|
|Citations:||Web of Science®. Times Cited: 35|
Scopus®. Citation Count: 41
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page